Patents by Inventor Geoffrey Wright

Geoffrey Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10849860
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: December 1, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Publication number: 20200368179
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: August 10, 2020
    Publication date: November 26, 2020
    Inventors: Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
  • Publication number: 20200323792
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
  • Patent number: 10796492
    Abstract: A system for providing a configurable virtual reality environment model includes a plurality of wall panels that are removeably interconnectable with each other without a need for tools. A plurality of floor sections are removeably interconnectable without a need for tools and include a connection interface for removeably connecting the wall panels to the plurality of floor sections. The plurality of wall panels are configured to place physical walls in a location that corresponds to a virtual wall located within a virtual reality world such that when a virtual reality display shows the user touching a wall in the virtual reality world, the user feels the physical wall placed in the configurable virtual reality environment. At least one network accessible component associated with a portion of the plurality of wall panels provides tactile feedback to a user responsive to the user coming within a predetermined distance of a wall panel.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: October 6, 2020
    Assignee: EXPLORING, INC.
    Inventors: Jovan Hutton Pulitzer, David Walens, Matthew Kelly, Geoffrey Wright
  • Publication number: 20200297656
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKLS; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 24, 2020
    Inventors: Geoffrey GUY, Stephen Wright, Orrin Devinsky
  • Patent number: 10765643
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: September 8, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 10709671
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: July 14, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 10709674
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: July 14, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 10693997
    Abstract: Embodiments of the present disclosure pertain to network based machine learning generated simulations. In one embodiment, the present disclosure includes a computer implemented method comprising sending first code comprising a programmable calculator from a server system to a client system across a network. A data request is sent to a database, the data request configured to retrieve data from the database comprising a plurality of fields and a target field. The retrieved data is processed using a machine learning algorithm to produce a weight for each field of the plurality of fields and a scoring data structure. The fields and the scoring data structure are sent to the client system across the network. A user selects values for the plurality of fields and the programmable calculator is configured based on the scoring data structure to generate a simulated value for the target field based on the user selected values.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: June 23, 2020
    Assignee: SAP SE
    Inventors: Katherine Wright, Sepideh Hashtroodi, Teresa Hsin Yi Su, Flavia Moser, Sajjad Gholami, Zeyu Ni, Geoffrey Neil Peters
  • Publication number: 20200179303
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Orrin DEVINSKY
  • Patent number: 10653641
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 19, 2020
    Assignee: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Publication number: 20200138738
    Abstract: The present invention relates in the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Surge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Application
    Filed: January 8, 2020
    Publication date: May 7, 2020
    Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Anne COMI
  • Patent number: 10603288
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 31, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 10583096
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: March 10, 2020
    Assignee: GW RESEARCH LIMITED
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Anne Comi
  • Publication number: 20200069608
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Publication number: 20200000741
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: September 13, 2019
    Publication date: January 2, 2020
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Publication number: 20190380638
    Abstract: A method of assessing the balance impairment of a subject includes the steps of presenting the subject with a static scene on a display, collecting a first set of orientation measurements, presenting the subject with an unstable scene on a display, collecting a second set of orientation measurements, storing the first and second sets of orientation measurements on a computing device, referenced to a set of time indices, and calculating a balance score for the subject by comparing the second set of orientation measurements with the first set of orientation measurements. A system for assessing the balance impairment of a subject is also disclosed.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 19, 2019
    Inventor: William Geoffrey Wright
  • Publication number: 20190371069
    Abstract: A system for providing a configurable virtual reality environment model includes a plurality of wall panels that are removeably interconnectable with each other without a need for tools. A plurality of floor sections are removeably interconnectable without a need for tools and include a connection interface for removeably connecting the wall panels to the plurality of floor sections. The plurality of wall panels are configured to place physical walls in a location that corresponds to a virtual wall located within a virtual reality world such that when a virtual reality display shows the user touching a wall in the virtual reality world, the user feels the physical wall placed in the configurable virtual reality environment. At least one network accessible component associated with a portion of the plurality of wall panels provides tactile feedback to a user responsive to the user coming within a predetermined distance of a wall panel.
    Type: Application
    Filed: March 15, 2019
    Publication date: December 5, 2019
    Inventors: Jovan Hutton Pulitzer, David Walens, Matthew Kelly, Geoffrey Wright
  • Publication number: 20190321307
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has It been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a Cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form.
    Type: Application
    Filed: December 13, 2017
    Publication date: October 24, 2019
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Livio Luongo
  • Publication number: 20190247324
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Application
    Filed: October 2, 2018
    Publication date: August 15, 2019
    Inventors: Benjamin Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi